Pratap Khedkar co-wrote this blog post with Arun Shastri.
At The Wall Street Journal Health Forum, held in Washington D.C. on April 30, Novartis Chief Executive Vas Narasimhan called artificial intelligence “another tool in the toolbox.” This viewpoint diverges from recent notions that AI is a critical capability that’s going to change the way that pharma companies do business. In fact, industry experts have hoped that the dwindling return on investments for R&D (the current 3% ROI is predicted to hit 0% by 2020) could be reversed by employing AI-based technologies in drug discovery. There are more than 100 AI startups in this field that have received generous investments from venture capital. Yet, IBM has discontinued sales of its Watson AI system for drug discovery.